Phenotype of Human Hematopoietic Cells Engrafted in NOD/Scid Mice
| Mouse No. . | Drug Exposure After PBPC Enrichment . | Total Number of Viable Cells Transplanted (×103) . | % of Human Cells 6-10 Weeks After Transplantation . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | CD34+ . | L87/4 (stromal) . | CD45+ . | CD13+ . | CD19+ . | CD34+ . | CD38+ . | CD61+ . | GPA+ . |
| 1 | no | 1,000 | — | 21 | 2.2 | 19 | 1.2 | ND | 0.3 | 0.2 |
| 2 | no | 1,000 | — | 17 | 1.6 | 15 | 1.1 | ND | 0.2 | 0.3 |
| 3 | no | 1,000 | — | 29 | 1.8 | 22 | 1.5 | ND | 0.3 | 0.5 |
| 4 | no | 1,000 | — | 17 | 0.9 | 15 | 1.4 | ND | 0.2 | 0.3 |
| 5 | no | 1,000 | — | 28 | 2.7 | 19 | 1.4 | ND | 0.5 | 0.4 |
| 6 | 5-FU, SCF, IL-3 | 446 | — | 9.5 | 0.7 | 7.7 | 1.1 | ND | 0.6 | 0.1 |
| 7 | 5-FU, SCF, IL-3 | 233 | — | 32 | 1.9 | 28 | 1.3 | ND | 0.2 | 0.3 |
| 8 | 5-FU, SCF, IL-3 | 75 | — | 7.8 | 1.1 | 5.2 | 0.5 | ND | 0.1 | 0.3 |
| 9 | 5-FU, SCF, IL-3 | 22 | — | 14 | 0.8 | 13 | 0.7 | ND | 0.2 | 0.3 |
| 10 | 5-FU, SCF, IL-3 | 5.8 | — | 5.5 | 0.9 | 4.1 | 0.3 | ND | 0.1 | 0.2 |
| 11 | 5-FU, SCF, IL-3 | 4.6 | — | 23 | 1.8 | 18 | 1.0 | 22 | 0.2 | 0.1 |
| 12 | 5-FU, SCF, IL-3 | 4.6 | — | 9.6 | 0.2 | 8.0 | 0.4 | 8.4 | 0.1 | 0.1 |
| 13 | 5-FU, SCF, IL-3 | 2.4 | — | 17 | 1.1 | 15 | 1.2 | 16 | 0.1 | 0.1 |
| 14 | 5-FU, SCF, IL-3 | 2.0 | — | 3.7 | 0.2 | 2.9 | 0.6 | 3.1 | 0.2 | 0.1 |
| 15 | 5-FU, SCF, IL-3 | 1.3 | 5.3 | 0.3 | 4.8 | 1.0 | 5.1 | 0.9 | 0.6 | |
| 16 | MF and taxol | 616 | 1,000 | 58 | 14 | 34 | 1.3 | 55 | 0.8 | 2.6 |
| 17 | MF and taxol | 399 | 1,000 | 61 | 11 | 32 | 1.8 | 43 | 1.2 | 3.0 |
| 18 | MF and taxol | 223 | 1,000 | 33 | 3.7 | 17 | 0.3 | 31 | 0.1 | 1.0 |
| 19 | MF and taxol | 185 | 1,000 | 21 | 1.3 | 16 | 0.5 | 19 | 0.2 | 0.7 |
| 20 | MF and taxol | 87 | 1,000 | 37 | 4.2 | 28 | 1.2 | 27 | 0.4 | 1.2 |
| 21 | MF and taxol | 0.28 | — | 5.4 | 0.2 | 4.1 | 0.1 | 4.8 | 0.1 | 0.2 |
| 22 | MF and taxol | 0.27 | — | 12 | 0.5 | 7.3 | 0.3 | 11 | 0.2 | 0.1 |
| 23 | MF and taxol | 0.26 | — | 3.6 | 0.1 | 2.7 | 0.2 | 2.9 | 0.1 | 0.1 |
| 24 | MF and taxol | 0.21 | — | 14 | 0.9 | 8.4 | 0.8 | 10 | 0.2 | 0.2 |
| 25 | MF and taxol | 0.18 | — | 6.0 | 0.5 | 5.6 | 1.3 | 5.5 | 0.1 | 0.1 |
| 26 | MF and taxol | 0.19 | 1,000 | 24 | 1.9 | 19 | 1.1 | 22 | 1.1 | 0.2 |
| 27 | MF and taxol | 0.16 | 1,000 | 17 | 1.4 | 16 | 1.3 | 15 | 0.2 | 0.3 |
| 28 | MF and taxol | 0.14 | 1,000 | 13 | 1.1 | 13 | 0.7 | 12 | 0.1 | 0.1 |
| 29 | MF and taxol | 0.13 | 1,000 | 27 | 2.8 | 24 | 1.3 | 25 | 0.6 | 0.1 |
| 30 | MF and taxol | 0.12 | 1,000 | 18 | 1.2 | 16 | 1.7 | 16 | 0.9 | 0.3 |
| Mouse No. . | Drug Exposure After PBPC Enrichment . | Total Number of Viable Cells Transplanted (×103) . | % of Human Cells 6-10 Weeks After Transplantation . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | CD34+ . | L87/4 (stromal) . | CD45+ . | CD13+ . | CD19+ . | CD34+ . | CD38+ . | CD61+ . | GPA+ . |
| 1 | no | 1,000 | — | 21 | 2.2 | 19 | 1.2 | ND | 0.3 | 0.2 |
| 2 | no | 1,000 | — | 17 | 1.6 | 15 | 1.1 | ND | 0.2 | 0.3 |
| 3 | no | 1,000 | — | 29 | 1.8 | 22 | 1.5 | ND | 0.3 | 0.5 |
| 4 | no | 1,000 | — | 17 | 0.9 | 15 | 1.4 | ND | 0.2 | 0.3 |
| 5 | no | 1,000 | — | 28 | 2.7 | 19 | 1.4 | ND | 0.5 | 0.4 |
| 6 | 5-FU, SCF, IL-3 | 446 | — | 9.5 | 0.7 | 7.7 | 1.1 | ND | 0.6 | 0.1 |
| 7 | 5-FU, SCF, IL-3 | 233 | — | 32 | 1.9 | 28 | 1.3 | ND | 0.2 | 0.3 |
| 8 | 5-FU, SCF, IL-3 | 75 | — | 7.8 | 1.1 | 5.2 | 0.5 | ND | 0.1 | 0.3 |
| 9 | 5-FU, SCF, IL-3 | 22 | — | 14 | 0.8 | 13 | 0.7 | ND | 0.2 | 0.3 |
| 10 | 5-FU, SCF, IL-3 | 5.8 | — | 5.5 | 0.9 | 4.1 | 0.3 | ND | 0.1 | 0.2 |
| 11 | 5-FU, SCF, IL-3 | 4.6 | — | 23 | 1.8 | 18 | 1.0 | 22 | 0.2 | 0.1 |
| 12 | 5-FU, SCF, IL-3 | 4.6 | — | 9.6 | 0.2 | 8.0 | 0.4 | 8.4 | 0.1 | 0.1 |
| 13 | 5-FU, SCF, IL-3 | 2.4 | — | 17 | 1.1 | 15 | 1.2 | 16 | 0.1 | 0.1 |
| 14 | 5-FU, SCF, IL-3 | 2.0 | — | 3.7 | 0.2 | 2.9 | 0.6 | 3.1 | 0.2 | 0.1 |
| 15 | 5-FU, SCF, IL-3 | 1.3 | 5.3 | 0.3 | 4.8 | 1.0 | 5.1 | 0.9 | 0.6 | |
| 16 | MF and taxol | 616 | 1,000 | 58 | 14 | 34 | 1.3 | 55 | 0.8 | 2.6 |
| 17 | MF and taxol | 399 | 1,000 | 61 | 11 | 32 | 1.8 | 43 | 1.2 | 3.0 |
| 18 | MF and taxol | 223 | 1,000 | 33 | 3.7 | 17 | 0.3 | 31 | 0.1 | 1.0 |
| 19 | MF and taxol | 185 | 1,000 | 21 | 1.3 | 16 | 0.5 | 19 | 0.2 | 0.7 |
| 20 | MF and taxol | 87 | 1,000 | 37 | 4.2 | 28 | 1.2 | 27 | 0.4 | 1.2 |
| 21 | MF and taxol | 0.28 | — | 5.4 | 0.2 | 4.1 | 0.1 | 4.8 | 0.1 | 0.2 |
| 22 | MF and taxol | 0.27 | — | 12 | 0.5 | 7.3 | 0.3 | 11 | 0.2 | 0.1 |
| 23 | MF and taxol | 0.26 | — | 3.6 | 0.1 | 2.7 | 0.2 | 2.9 | 0.1 | 0.1 |
| 24 | MF and taxol | 0.21 | — | 14 | 0.9 | 8.4 | 0.8 | 10 | 0.2 | 0.2 |
| 25 | MF and taxol | 0.18 | — | 6.0 | 0.5 | 5.6 | 1.3 | 5.5 | 0.1 | 0.1 |
| 26 | MF and taxol | 0.19 | 1,000 | 24 | 1.9 | 19 | 1.1 | 22 | 1.1 | 0.2 |
| 27 | MF and taxol | 0.16 | 1,000 | 17 | 1.4 | 16 | 1.3 | 15 | 0.2 | 0.3 |
| 28 | MF and taxol | 0.14 | 1,000 | 13 | 1.1 | 13 | 0.7 | 12 | 0.1 | 0.1 |
| 29 | MF and taxol | 0.13 | 1,000 | 27 | 2.8 | 24 | 1.3 | 25 | 0.6 | 0.1 |
| 30 | MF and taxol | 0.12 | 1,000 | 18 | 1.2 | 16 | 1.7 | 16 | 0.9 | 0.3 |
Sublethally irradiated animals received mobilized peripheral blood hematopoietic progenitors enriched by immunoaffinity removal of lineage-positive cells. In some studies, cells were exposed to both mafosfamide and taxol or cultured for 7 days in the presence of 5-FU, SCF, and IL-3. On some occasions, animals received also irradiated L87/4 stromal cells.
Abbreviations: PBPC, peripheral blood progenitor cell; GPA, glycophorin A; ND, not done; FU, fluorouracil; SCF, stem cell factor; IL, interleukin; MF, mafosfamide.